AZD 2811

Drug Profile

AZD 2811

Alternative Names: AZD 1152 hQPA; AZD2811

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; BIND Therapeutics
  • Developer AstraZeneca; Pfizer
  • Class Acetamides; Antineoplastics; Fluorobenzenes; Pyrazoles; Quinazolines
  • Mechanism of Action Aurora kinase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Small cell lung cancer
  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Solid tumours
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 14 Dec 2017 Samsung Medical Center plans the phase II SUKSES-N3 trial for Small cell lung cancer (Second-line therapy or greater) (IV) in December 2017 (NCT03366675)
  • 09 Dec 2017 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 01 Dec 2017 Phase-II clinical trials in Small cell lung cancer (Monotherapy, Second-line therapy or greater) in South Korea (IV) (NCT03366675)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top